InsiderTrades.com logo
Learn to Customize Your Own Options Trading Strategy
From RJO Futures   |   Ad
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel

ADIL Insider Trading (Adial Pharmaceuticals)

Insider Ownership Percentage: 33.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $375,000.00

Adial Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Adial Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adial Pharmaceuticals Share Price & Price History

Current Price: $2.45
Price Change: ▲ Price Increase of +0.05 (2.08%)
As of 07/29/2021 01:00 AM ET

This chart shows the closing price history over time for ADIL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Learn to Customize Your Own Options Trading Strategy
From RJO Futures   |   Ad
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel

Adial Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/6/2021Bankole A. JohnsonInsiderSell150,000$2.50$375,000.001,055View SEC Filing Icon  
3/27/2020James W Jr. NewmanDirectorBuy19,644$1.28$25,144.3215,000View SEC Filing Icon  
3/25/2020William B Stilley IIICEOBuy12,348$1.13$13,953.24703,285View SEC Filing Icon  
12/12/2019Bankole A. JohnsonInsiderSell150,000$1.00$150,000.00351,055View SEC Filing Icon  
3/29/2019Bankole A. JohnsonInsiderBuy73,100$3.29$240,499.00View SEC Filing Icon  
See Full Table
Insider Buying at Adial Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Adial Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Adial Pharmaceuticals (NASDAQ:ADIL)

4.23% of Adial Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ADIL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Adial Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/17/2021Golden Green Inc.24,700$63K0.0%N/A0.134%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP31,410$76K0.0%+68.8%0.179%Search for SEC Filing on Google Icon
5/13/2021Barclays PLC15,850$38K0.0%N/A0.091%Search for SEC Filing on Google Icon
5/12/2021Rede Wealth LLC15,000$36K0.0%N/A0.086%Search for SEC Filing on Google Icon
5/10/2021Oppenheimer & Co. Inc.14,500$35K0.0%N/A0.083%Search for SEC Filing on Google Icon
5/4/2021Commonwealth Equity Services LLC22,050$53K0.0%+107.3%0.126%Search for SEC Filing on Google Icon
4/22/2021Private Advisor Group LLC36,650$89K0.0%N/A0.212%Search for SEC Filing on Google Icon
3/8/2021Dimensional Fund Advisors LP18,612$32K0.0%N/A0.129%Search for SEC Filing on Google Icon
2/25/2021Dimensional Fund Advisors LP18,612$32K0.0%N/A0.129%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC98,900$0.17M0.0%+6.5%0.687%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC18,902$42K0.0%N/A0.131%Search for SEC Filing on Google Icon
8/14/2020Bank of America Corp DE150,000$0.21M0.0%N/A1.115%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.293,908$0.49M0.0%-3.2%2.875%Search for SEC Filing on Google Icon
2/14/2019Two Sigma Investments LP11,775$60K0.0%N/A0.180%Search for SEC Filing on Google Icon
2/13/2019Geode Capital Management LLC13,581$69K0.0%N/A0.207%Search for SEC Filing on Google Icon
2/8/2019BlackRock Inc.205,684$1.05M0.0%N/A3.137%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Read More on Adial Pharmaceuticals

Today's Range

Now: $2.45
Low: $2.36
High: $2.49

50 Day Range

MA: $2.64
Low: $2.33
High: $3.13

52 Week Range

Now: $2.45
Low: $1.14
High: $4.00

Volume

203,334 shs

Average Volume

844,623 shs

Market Capitalization

$45.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Who are the company insiders with the largest holdings of Adial Pharmaceuticals?

Adial Pharmaceuticals' top insider shareholders include:
  1. William B Stilley III (CEO)
  2. Bankole A Johnson (Insider)
  3. James W Jr Newman (Director)

Who are the major institutional investors of Adial Pharmaceuticals?

Adial Pharmaceuticals' top institutional investors include:
  1. Golden Green Inc. — 0.13%

Which institutional investors are buying Adial Pharmaceuticals stock?

Within the last quarter, ADIL stock was acquired by institutional investors including:
  1. Golden Green Inc.
Within the previous year, these company insiders have bought Adial Pharmaceuticals stock:
  1. William B Stilley III (CEO)
  2. Bankole A Johnson (Insider)
Three Cryptocurrencies to Hold in 2021
From Investorplace Media   |   Ad
In 2021, Dogecoin went up over 12,000%. SafeMoon went up more than 20,000%...

But if you missed those gains, there is still time to get in on the digital currency boom.

Luke Lango – InvestorPlace’s resident crypto expert – just released the names of 3 tokens every investor should own in a free report.
Click here to claim your copy today.
pixel